Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kala Pharmaceuticals (KALA) stocks in Canada

Learn how to easily invest in Kala Pharmaceuticals stocks.

Kala Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Kala Pharmaceuticals stocks (KALA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.03 – a decrease of 4.93% over the previous week. Kala Pharmaceuticals employs 188 staff and has a trailing 12-month revenue of around $11.6 million.

How to buy shares in Kala Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KALA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kala Pharmaceuticals stock price (NASDAQ:KALA)

Use our graph to track the performance of KALA stocks over time.

Kala Pharmaceuticals shares at a glance

Information last updated 2022-01-23.
Latest market close$0.77
52-week range$0.75 - $9.97
50-day moving average $1.49
200-day moving average $3.58
Wall St. target price$6.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.03

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Kala Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Kala Pharmaceuticals price performance over time

Historical closes compared with the close of $0.771 from 2022-01-27

1 week (2022-01-21) -4.87%
1 month (2021-12-28) -35.75%
3 months (2021-10-28) -55.43%
6 months (2021-07-28) -79.22%
1 year (2021-01-28) -89.84%
2 years (2020-01-28) -89.22%
3 years (2019-01-28) 5.24
5 years (2017-01-24) N/A

Kala Pharmaceuticals financials

Revenue TTM $11.6 million
Gross profit TTM $4.2 million
Return on assets TTM -33.25%
Return on equity TTM -150.63%
Profit margin 0%
Book value $0.94
Market capitalisation $53.1 million

TTM: trailing 12 months

Kala Pharmaceuticals share dividends

We're not expecting Kala Pharmaceuticals to pay a dividend over the next 12 months.

Kala Pharmaceuticals share price volatility

Over the last 12 months, Kala Pharmaceuticals's shares have ranged in value from as little as $0.7508 up to $9.969. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kala Pharmaceuticals's is 0.2142. This would suggest that Kala Pharmaceuticals's shares are less volatile than average (for this exchange).

Kala Pharmaceuticals overview

Kala Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site